{"id":19500,"date":"2023-05-26T09:18:34","date_gmt":"2023-05-26T09:18:34","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19500"},"modified":"2023-05-26T09:32:38","modified_gmt":"2023-05-26T09:32:38","slug":"faster-throughput-together-new-streamlined-solution-for-immunosuppressant-analysis-by-lc-ms-ms","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/faster-throughput-together-new-streamlined-solution-for-immunosuppressant-analysis-by-lc-ms-ms\/","title":{"rendered":"Faster throughput \u2013 together | New streamlined solution for immunosuppressant analysis by LC-MS\/MS"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Faster throughput \u2013 together | New streamlined solution for immunosuppressant analysis by LC-MS\/MS<\/h1>\/ in Featured Articles<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Faster throughput \u2013 together | New streamlined solution for immunosuppressant analysis by LC-MS\/MS<\/h2>\n

by Mika\u00ebl Levi<\/em><\/p>\n

To face increasing demands on their time and resources, chemical laboratories need easier-to-handle solutions with faster turnaround times, lower costs per sample and full compliance with ever-stricter regulatory standards. Recent work by Alsachim using Shimadzu equipment and software has now led to an optimized high-throughput analytical solution that delivers same-day results for therapeutic drug monitoring of immunosuppressants.<\/h3>\n

<\/p>\n

Background<\/h4>\n

Therapeutic drug monitoring (TDM) is a multidisciplinary science that aims to understand the factors that determine the dose\u2013effect relationship and to use this knowledge to optimize drug treatment [1\u20133].<\/p>\n

In most laboratories, automated immunoassay platforms dominate in TDM. However, these may produce biased results due to the cross reactivity of the active metabolites. This complication may be compounded by batch-to-batch heterogeneity in antibodies or reagent quality, high-dose-hook effects and a high cost per analysis [4].<\/p>\n

As precision medicine emerges as an approach to individualized patient treatment \u2013 i.e. addressing a specific disease and taking into account individual variability in genes, environment and lifestyle \u2013 TDM is likely to have an even greater impact on dose adjustment. Already, this new application for TDM is increasing the number of samples to assay, as well as the pressure for rapid turnaround times. Adding to these challenges is the need to comply with European regulations for in vitro diagnostics that came into force in May 2022 and which have dramatically heightened the need for certified analytical solutions.<\/p>\n

In this article, we highlight a time-saving, complete and fully compliant high-throughput solution for immunosuppressant analysis \u2013 created by a combination of liquid chromatography and tandem mass spectrometry (LC-MS\/MS) with automated sample preparation and a dedicated reagent kit.<\/p>\n

LC-MS\/MS for TDM<\/h4>\n

Liquid chromatography (LC) techniques have been used in TDM for several decades. However, despite the impact of ultra-high-performance LC [5\u20137], such detection techniques are limited in terms of specificity \u2013 often resulting in extensive sample cycle times and poor sensitivity [1].<\/p>\n

Mass spectrometry (MS) is now regarded as a key technique for laboratories delivering robust platforms with highly selective and sensitive detection [8]. The capability of MS in the development of assays for individual drugs and in multiplexing analyte panels creates new opportunities while expanding the number of drug assays.<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
Figure 1. Calibrator and control positioning in robot racks<\/div><\/div><\/div>
\n

Figure 1. Calibrator and control positioning in robot racks<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

Automated sample management and preparation<\/h4>\n

Biological fluids are highly complex matrices which present challenges in matrix management, as endogenous and exogenous components result in compound and system-specific effects in MS. Negating the effects of the matrix must be carefully considered in all sample preparation and management protocols. Matrix effects can lead to isobaric interference, particulate clogging and ion suppression or enhancement, resulting in a difference between the signal intensity detected in a neat standard solution.<\/p>\n

To help reduce the impact of matrix effects on bioanalytical assays, there are several strategies open to the analyst. One of the most important techniques is to use appropriate and validated internal standards (IS), particularly stable-isotope-labelled analogues (SIL-ISTD), to help correct for ion signal changes and handling errors in sampling preparation protocols. However, for many assays the effect of high inter- and intra-patient variability in endogenous molecule concentrations also requires sample clean-up using extraction or purification techniques.<\/p>\n

For high-throughput assays, the design of the sample preparation method can benefit greatly from automated systems. Robotic liquid handlers with multiple pipettes, such as the Hamilton Microlab Star, can manage simple or complex sample preparation protocols with a high number of samples.<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
Figure 2. Solution precision and stability for measured concentrations (left) and internal standard area (right)<\/div><\/div><\/div>
\n

Figure 1. Calibrator and control positioning in robot racks<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

Immunosuppressant drugs<\/h4>\n

Immunosuppressant drugs are indicated to reduce the activity of the immune system to prevent transplant rejection. Circulating concentrations of these compounds should remain within a narrow therapeutic window, as overdosing can cause serious toxicity and long-term morbidity, while underdosing can cause graft rejection [3]. As there is a high pharmacokinetic variability for immunosuppressant drugs between individual patients, TDM is now an established approach to mitigate the risks associated with organ transplantation.<\/p>\n

Several commercial immunoassays are available for the TDM of immunosuppressants; however, all immunoassays show a significant positive bias compared to LC-MS\/MS methods [9]. Despite the availability of automated immunoassays, each test is restricted to one analyte per test even though multiple immunosuppressants are used with an individual patient in many clinical settings [1,10]. The following paragraphs describe a new streamlined and automated LC-MS\/MS method for the routine TDM analysis of immunosuppressants.<\/p>\n

Combining individual solutions<\/h4>\n

To meet the need for high-throughput analysis, a DOSIMMUNE\u2122 kit (Alsachim) was adapted to robotic liquid handling. This kit, validated and CE-IVD marked with manual sample preparation, provides all the necessary reagents and consumables to monitor immuno-suppressants in whole blood by LC-MS\/MS. Calibrator and control vials can be directly positioned in robot racks (Fig. 1). However, liquid handlers have a larger dead volume that cannot be sucked up, compared to manual pipetting. So, two vials of each calibrator and control level were pooled prior to installation on the racks. With this adjustment, calibrators and controls can be used for an entire week before being replaced.<\/p>\n

In order to reduce the number of consumables and protocol steps, an IS solution was mixed directly with the extraction buffer. The mixture can be then dispensed in a reservoir or through a solvent delivery unit.<\/p>\n

Workflow optimization of the liquid handler was conducted to reach the shortest possible preparation time while maintaining the performance obtained with the manual protocol. Most efforts were concentrated on the blood resuspension step. To obtain accurate results, samples should be homogeneous during sampling. Therefore, resuspension of each sample was performed just before sampling. A specific protocol was developed using several sequences of aspiration\/delivery using the sample height follow-up function of the robot. With this protocol, samples with volumes ranging from 0.5 to 5 mL and haematocrit values from 30 to 70% were successfully homogenized with a 60% time reduction compared to similar protocols observed in laboratories. Vortex and centrifugation time\/speed parameters were also optimized and operations parallelized as much as possible. Finally, a complete 96-well plate (blank plus 6 calibrators, 4 controls and 85 samples) was provided ready-to-be-assayed in 45 minutes. Compared to traditional robotic solutions for immunosuppressant analysis, this corresponds to a 50% reduction in preparation time.<\/p>\n

Immunosuppressants are complex hydrophobic compounds that are known to produce carry-over in LC. The new Nexera X3 LC system (Shimadzu) has improved rinsing capabilities that dramatically reduce the time needed to clean inside the needle. Consequently, the LC-MS\/MS cycle time was reduced from 2.1 to 1.5 min (injection-to-injection). When considering the number of samples to be assayed, this 30% reduction greatly improves turnaround time.<\/p>\n

Evaluation and validation<\/h4>\n

Precision and stability of the solution were evaluated by sequentially preparing three plates containing only the same control at low\u2013mid levels (tacrolimus, sirolimus and everolimus at approximately 8 \u00b5g\/L, cyclosporin A at approximately 145 \u00b5g\/L) as unknown sample. The first plate included calibrators and controls; other plates included controls. Plates were assayed within the same sequence. Finally, 272 data points were obtained across the three plates. Figure 2 shows the measured concentrations for all compounds and the measured IS peak area. The relative standard deviation of concentrations or peak areas were well below the usually accepted criteria of 15%. This demonstrated that the MS calibration was stable, that the sample preparation precision was excellent and that reagents were stable on the robot tray. A typical chromatogram of such low\u2013mid level control samples is shown in Figure 3.<\/p>\n

The method including sample preparation was validated according to international guidelines for bioanalytical methods (ICH M10 [11], CLSI C62-A [12]). In addition, clinical performance evaluation was evaluated by comparing the results obtained on real patient samples using manual preparation. Statistical analysis demonstrated that the methods were in close agreement and commutable. Figure 4 shows the results of Passing\u2013Bablok regression analysis.<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
Figure 3. Typical control chromatogram containing (left to right) cyclosporin A, tacrolimus, everolimus and sirolimus<\/div><\/div><\/div>
\n

Figure 3. Typical control chromatogram containing (left to right) cyclosporin A, tacrolimus, everolimus and sirolimus<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

Immunosuppressant drugs<\/h4>\n

Immunosuppressant drugs are indicated to reduce the activity of the immune system to prevent transplant rejection. Circulating concentrations of these compounds should remain within a narrow therapeutic window, as overdosing can cause serious toxicity and long-term morbidity, while underdosing can cause graft rejection [3]. As there is a high pharmacokinetic variability for immunosuppressant drugs between individual patients, TDM is now an established approach to mitigate the risks associated with organ transplantation.<\/p>\n

Several commercial immunoassays are available for the TDM of immunosuppressants; however, all immunoassays show a significant positive bias compared to LC-MS\/MS methods [9]. Despite the availability of automated immunoassays, each test is restricted to one analyte per test even though multiple immunosuppressants are used with an individual patient in many clinical settings [1,10]. The following paragraphs describe a new streamlined and automated LC-MS\/MS method for the routine TDM analysis of immunosuppressants.<\/p>\n

Combining individual solutions<\/h4>\n

To meet the need for high-throughput analysis, a DOSIMMUNE\u2122 kit (Alsachim) was adapted to robotic liquid handling. This kit, validated and CE-IVD marked with manual sample preparation, provides all the necessary reagents and consumables to monitor immuno-suppressants in whole blood by LC-MS\/MS. Calibrator and control vials can be directly positioned in robot racks (Fig. 1). However, liquid handlers have a larger dead volume that cannot be sucked up, compared to manual pipetting. So, two vials of each calibrator and control level were pooled prior to installation on the racks. With this adjustment, calibrators and controls can be used for an entire week before being replaced.<\/p>\n

In order to reduce the number of consumables and protocol steps, an IS solution was mixed directly with the extraction buffer. The mixture can be then dispensed in a reservoir or through a solvent delivery unit.<\/p>\n

Workflow optimization of the liquid handler was conducted to reach the shortest possible preparation time while maintaining the performance obtained with the manual protocol. Most efforts were concentrated on the blood resuspension step. To obtain accurate results, samples should be homogeneous during sampling. Therefore, resuspension of each sample was performed just before sampling. A specific protocol was developed using several sequences of aspiration\/delivery using the sample height follow-up function of the robot. With this protocol, samples with volumes ranging from 0.5 to 5 mL and haematocrit values from 30 to 70% were successfully homogenized with a 60% time reduction compared to similar protocols observed in laboratories. Vortex and centrifugation time\/speed parameters were also optimized and operations parallelized as much as possible. Finally, a complete 96-well plate (blank plus 6 calibrators, 4 controls and 85 samples) was provided ready-to-be-assayed in 45 minutes. Compared to traditional robotic solutions for immunosuppressant analysis, this corresponds to a 50% reduction in preparation time.<\/p>\n

Immunosuppressants are complex hydrophobic compounds that are known to produce carry-over in LC. The new Nexera X3 LC system (Shimadzu) has improved rinsing capabilities that dramatically reduce the time needed to clean inside the needle. Consequently, the LC-MS\/MS cycle time was reduced from 2.1 to 1.5 min (injection-to-injection). When considering the number of samples to be assayed, this 30% reduction greatly improves turnaround time.<\/p>\n

Evaluation and validation<\/h4>\n

Precision and stability of the solution were evaluated by sequentially preparing three plates containing only the same control at low\u2013mid levels (tacrolimus, sirolimus and everolimus at approximately 8 \u00b5g\/L, cyclosporin A at approximately 145 \u00b5g\/L) as unknown sample. The first plate included calibrators and controls; other plates included controls. Plates were assayed within the same sequence. Finally, 272 data points were obtained across the three plates. Figure 2 shows the measured concentrations for all compounds and the measured IS peak area. The relative standard deviation of concentrations or peak areas were well below the usually accepted criteria of 15%. This demonstrated that the MS calibration was stable, that the sample preparation precision was excellent and that reagents were stable on the robot tray. A typical chromatogram of such low\u2013mid level control samples is shown in Figure 3.<\/p>\n

The method including sample preparation was validated according to international guidelines for bioanalytical methods (ICH M10 [11], CLSI C62-A [12]). In addition, clinical performance evaluation was evaluated by comparing the results obtained on real patient samples using manual preparation. Statistical analysis demonstrated that the methods were in close agreement and commutable. Figure 4 shows the results of Passing\u2013Bablok regression analysis.<\/p>\n

Throughput and compliance<\/h4>\n

By adjusting the number of liquid handlers and LC-MS\/MS systems, it is possible to assay from 300 to almost 900 patient specimens in less than 10 working hours. Figure 5 shows an example of a suggested configuration to reach very high throughput.<\/p>\n

In addition to the analytical optimization, informatic connections were studied to be in line with the system speed. The liquid handler automatically generates the working list by scanning the patient tubes and this list is exported directly in the correct format to the Shimadzu LabSolutions software for LC-MS. With a few clicks, the sample assay sequence is created. Using adaptive flagging rules, the software proposes a review-by-exception that highlights the data that need to be looked at by the analyst. Double data validation is possible before sending the results to the laboratory information system through csv files or HL7 bidirectional connection.<\/p>\n

All of the instruments and software involved in this time-saving solution are CE-IVD certified. The DOSIMMUNE\u2122 kit has also been certified as CE-IVD with manual or automated sample preparation.<\/p>\n

In summary, an efficient and time-saving new method using an optimized and fully compliant combination of instruments, reagents and software now exists for high-throughput analysis
\nof immunosuppressants.<\/p>\n<\/div><\/section>
\n

References<\/strong><\/em><\/p>\n

1. Saint-Marcoux F, Sauvage FL, Marquet P. Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 2007;388(7):1327\u20131349 (https:\/\/link.springer.com\/article\/10.1007\/s00216-007-1320-1<\/a>).<\/em>
\n2. Adaway JE, Keevil BG. Therapeutic drug monitoring and LC-MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012;883\u2013884:33\u201349 (https:\/\/doi.org\/10.1016\/j.jchromb.2011.09.041<\/a>).<\/em>
\n3. Taylor PJ, Tai CH, Franklin ME, Pillans PI. The current role of liquid chro<\/em>matography-tandem mass spectrometry in therapeutic drug monitoring <\/em>of immunosuppressant and antiretroviral drugs. Clin Biochem 2011;44(1):14\u201320 (https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.06.012<\/a>).<\/em>
\n4. Vogeser M, Seger C. LC-MS\/MS in clinical chemistry. J Chromatogr B Analyt Technol Biomed Life Sci 2012;883\u2013884:1\u20132 <\/em>(https:\/\/doi.org\/10.1016\/j.jchromb.2012.01.001<\/a>).<\/em>
\n5. Barco S, Zunino A, D’Avolio A et al. A rapid and robust UHPLC-DAD method for the quantification of amphotericin B in human plasma. <\/em>J Pharm Biomed Anal 2017;138:142\u2013145 <\/em>(https:\/\/doi.org\/10.1016\/j.jpba.2017.01.048<\/a>).<\/em>
\n6. Toussaint B, Lanternier F, Woloch C et al. An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1046:26\u201333 (https:\/\/doi.org\/10.1016\/j.jchromb.2017.01.036<\/a>).<\/em>
\n7. Mistretta V, Dubois N, Denooz R, Charlier C. Simultaneous determination <\/em>of seven azole antifungal drugs in serum by ultra-high pressure liquid chromatography and diode array detection. Acta Clin Belg 2014;69(1):<\/em>= 53\u201361 (https:\/\/doi.org\/10.1179\/0001551213Z.00000000018<\/a>).<\/em>
\n8. Himmelsbach M. 10 years of MS instrumental developments–impact <\/em>on LC-MS\/MS in clinical chemistry. J Chromatogr B Analyt Technol Biomed Life Sci 2012;883\u2013884:3\u201317 <\/em>
\n(https:\/\/doi.org\/10.1016\/j.jchromb.2011.11.038<\/a>).<\/em>
\n9. Tszyrsznic W, Borowiec A, Pawlowska E et al. Two rapid ultra perfor<\/em>mance liquid chromatography\/tandem mass spectrometry (UPLC\/MS\/MS) methods with common sample pretreatment for therapeutic <\/em>drug monitoring of immunosuppressants compared to immunoassay. <\/em>J Chromatogr B Analyt Technol Biomed Life Sci 2013;928:9\u201315 <\/em>(https:\/\/doi.org\/10.1016\/j.jchromb.2013.03.014<\/a>).<\/em>
\n10. Aucella F, Lauriola V, Vecchione G et al. Liquid chromatography<\/em>tandem mass spectrometry method as the golden standard for therapeutic drug monitoring in renal transplant. J Pharm Biomed <\/em>Anal 2013;86:123\u2013126 (https:\/\/doi.org\/10.1016\/j.jpba.2013.08.001<\/a>).<\/em>
\n11. ICH guideline M10 on bioanalytical method validation EMA\/CHMP\/ICH\/172948\/2019. European Medicines Agency 2022. <\/em>
\n12. Liquid Chromatography-Mass spectrometry Methods \u2013 <\/em>Approved Guideline. CLSI document C62-A. Clinical and <\/em>Laboratory Standards Institute 2014.<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
Figure 4. Passing\u2013Bablok regression analysis for comparison of manual preparation and automated method<\/div><\/div><\/div>
\n

Figure 4. Passing\u2013Bablok regression analysis for comparison of manual preparation and automated method<\/em><\/p>\n<\/div><\/section>
\n

Figure 5. Example of high-throughput configuration<\/div><\/div><\/div>
\n

Figure 5. Example of high-throughput configuration<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

The author<\/strong><\/em><\/p>\n

Mika\u00ebl Levi<\/em>
\nAlsachim, Parc d’innovation – Les Scientifiques, 67400 Illkirch Graffenstaden, France<\/em><\/p>\n

Email: contact@alsachim.com<\/a><\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/div><\/section>
\n